Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.68% | -40.78% | 34.25% | -49.95% | 13.76% |
| Total Depreciation and Amortization | -100.00% | -88.37% | 290.91% | 10.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.20% | 223.22% | -116.38% | 1,108.36% | 262.73% |
| Change in Net Operating Assets | 117.10% | -164.24% | -375.06% | 317.46% | 49.14% |
| Cash from Operations | 34.25% | -32.06% | -73.81% | 24.99% | 22.51% |
| Capital Expenditure | -- | -- | -- | 100.00% | -200.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -163.95% | 551.66% | 245.61% |
| Cash from Investing | -- | -- | -163.95% | 552.64% | 245.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 69,500.00% | -100.00% | 19,537.10% | 1,741.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69,500.00% | -99.99% | 23,380.80% | 1,250.00% | -- |
| Foreign Exchange rate Adjustments | 16,033.33% | -98.99% | 845.71% | 112.80% | -112.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 174.79% | -130.10% | 145.43% | 494.98% | 63.99% |